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Abstract  Perfusion  CT  or  MRI  have  been  extensively  developed  over  the  last  years  and  are
accessible  on  most  imaging  machines.  Perfusion  CT  has  taken  a  major  place  in  the  assessment
of a  stroke.  Its  role  has  to  be  speciﬁed  for  the  diagnosis  and  treatment  of  the  vasospasm,
complicating  a  subarachnoid  hemorrhage.  Perfusion  MRI  should  be  included  in  the  assessment
of any  brain  tumor,  both  at  the  time  of  the  diagnosis  as  well  as  in  the  post-treatment  monitoring.
It is  included  in  the  multimodal  approach  required  for  the  optimum  treatment  of  this  disease.
The applications  in  epilepsy  and  the  neurodegenerative  diseases  are  in  the  evaluation  process.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
The  exploration  of  the  brain  by  radiology  can’t  be  summed  up  by  the  acquisition  of  morpho-
logical  information.  It  should  include  metabolic  data  (1H  MR  spectroscopy),  microstructural
data  (diffusion),  vascular  data  (perfusion  angiography)  and  functional  data  (activation
imaging).
Since  the  beginning  of  the  year  2000,  ﬁrst  pass  brain  perfusion  MRI  has  taken  off  and
has  become  unavoidable  for  the  characterization  and  monitoring  of  neoplastic  processes
[1—3].
Secondly,  with  the  appearance  of  MDCT  scanners  enabling  the  acquisition  of  several
slices  in  less  than  1  s,  the  perfusion  CT-scan  has  also  developed.  Quickly  and  easily  avail-
able,  this  technique  has  widely  imposed  itself  in  emergencies,  in  particular  for  the  care
of  stroke  victims  [4,5].  It  is  also  a  pertinent  tool  to  assess  the  vasospasm  complicat-
ing  subarachnoid  hemorrhages,  thereby  enabling  the  application  of  the  best  therapeutic
strategy.
We  will  detail  the  value  of  perfusion  imaging  in  the  different  clinical  applications
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cute brain ischemia
he  ﬁrst  cause  of  disability  in  the  adult  in  developed
ountries  and  the  third  leading  cause  of  mortality,  the  stroke
r  cerebrovascular  accident  (CVA)  is  a  public  health  prob-
em  receiving  optimum  care  by  neurological  critical  care
nits  (NCCU).  Imaging  in  standard  slices  with  angiographic
equences  associated  with  diffusion  MRI  (with  or  without
erfusion)  and  the  perfusion  CT-scan  are  the  different  means
vailable.  Used  to  advantage,  they  should  quickly,  and  with-
ut  delaying  the  therapeutic  care  of  the  patient,  indicate
 diagnosis  of  brain  ischemia  while  specifying  the  extent
f  the  lesion,  deﬁne  the  extent  of  the  perfusion  anomalies
nd  assess  their  reversibility,  search  for  the  cause  of  the
schemia  by  indicating  the  level  of  the  arterial  occlusion.
he  severe  functional  prognosis  perceived,  several  years
go,  as  an  inexplorable  fatality,  has  improved  considerably
ith  the  arrival  of  intravenous  or  intra-arterial  thrombo-
ysis  and  the  emergency  care  of  CVA,  fairly  close  to  that
f  infarction  of  the  myocardium.  In  a  study  carried  out  in
999,  only  3%  of  the  patients,  who  should  have  been  treated
ithin  the  ﬁrst  three  hours,  were  able  to  beneﬁt  from  throm-
olysis.  Although  the  time  before  arrival  at  a  NCCU  has
een  reduced,  due  to  improved  organization  of  care  and  the
ncreased  awareness  of  the  medical  and  paramedical  team
s  to  CVA,  it’s  still  interesting  to  try  and  extend  this  time,
ithout  it  harming  the  patient,  so  as  to  allow  him  to  beneﬁt
rom  the  greatest  number  of  adapted  treatments  [6],  and
ossibly  consider  arterial  recanalization.
Once  the  arterial  occlusion  has  been  assessed,  the  def-
nition  of  the  penumbra  (that  is,  the  hypoperfused  tissue
ith  a  risk  of  necrosis,  but  whose  damage  is  potentially
eversible)  is  the  cornerstone  of  therapeutic  care.  Treat-
ent  by  alteplase  leads  to  arterial  recanalization  and
egression  of  the  neurological  deﬁciency  as  a  function  of
he  extent  of  the  penumbra.  Studies  have  shown  the  value
f  intravenous  thrombolysis  carried  out  within  4  ½ h  after
he  onset  of  the  neurological  deﬁciency  [7].  Symptomatic
ntracranial  hemorrhages  due  to  the  alteplase  occur  at  a  rate
imilar  to  that  observed  when  the  delay  is  less  than  3  h  [8].
n  MRI  study,  including  diffusion  and  perfusion  parameters,
as  demonstrated  the  efﬁcacy  of  intravenous  thrombolysis
ith  6  h  [9].  The  real  challenge  is  to  identify  and  deﬁne  the
roﬁle  of  the  patients  that  may  beneﬁt  from  thrombolysis
ccording  to  the  time  before  treatment  with  respect  to  the
nset  of  the  clinical  deﬁciency.  The  difﬁculty  is  to  recognize
he  penumbra  and  differentiate  it  from  a  benign  oligemia.
ani  et  al.  [10]  and  Mishra  et  al.  [11]  point  out,  in  their
nalyses  of  the  literature,  the  different  deﬁnitions  in  CT-
can  and  MRI,  of  the  infracted  zones,  of  the  tissue  at  risk
nd  the  tissue  without  a  risk  of  ischemia.  The  parameters
sed  and  the  thresholds  chosen  vary  a  great  deal  accord-
ng  to  the  team.  Even  if  it’s  possible  to  lengthen  the  time
efore  thrombolysis,  the  precocity  of  the  care  remains  the
est  guarantee  of  a  good  functional  recovery.
T perfusionhe  ﬁrst  deﬁnitions  of  the  penumbra  and  infarction  rely  on
easurement  of  the  cerebral  blood  ﬂow  (CBF).  The  CBF  of
 normally  perfused  area  is  greater  than  40  mL/100  g/min,
he  CBF  of  a  zone  of  oligemia  is  between  20  and
P
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0  mL/100  g/min,  the  CBF  of  a  zone  of  penumbra  is  between
0  and  20  mL/100  g/min,  the  CBF  of  an  ischemic  zone  is
nder  10  mL/100  g/mn.  This  measurement  did  not  seem  to
e  robust,  since  the  CBF  varies  according  to  the  age  of
he  patient  and  is  three  times  as  high  in  the  grey  matter
GM)  than  in  the  white  matter  (WM),  leading  to  a  quantiﬁ-
ation  that  varies  according  to  the  percentage  of  GM  and
M  involved  by  the  delimitation  of  the  region  of  interest
ROI).  Wintermark  et  al.  [4]  described  the  obvious  superi-
rity  of  perfusion  CT  over  that  of  CT  without  injection  for
he  detection  of  CVA  and  showed  that  the  mean  transit  time
MTT)  mapping  is  most  sensitive  and  those  of  the  cerebral
lood  volume  (CBV)  and  the  CBF  the  most  speciﬁc.  They  also
oted  the  importance  of  cerebral  vascular  autoregulation.
n  infarction,  the  vascular  autoregulation  is  lost,  there  is
 reduction  in  the  CBF  and  CB.  In  the  penumbra,  there  is
 reduction  in  the  CBF  although  the  CBV  tries  to  be  main-
ained  by  vasodilatation  and  recruitment  of  the  collateral
athways.  In  case  of  inappropriate  perfusion,  they  observed
n  increase  in  the  CBF  and  CBV,  an  extension  of  the  MTT  and
TP  (time  to  peak  or  time  until  the  peak  value).  In  2006  [5],
hey  proposed  thresholds  that  are  currently  used  as  of  two
rains  perfusion  parameters:
a 145%  increase  in  the  MTT  with  respect  to  the  healthy
contralateral  tissue  is  the  threshold  value  to  deﬁne  tissue
at  risk.  It  predicts  the  ﬁnal  size  of  the  infarction  without
recanalization  on  the  monitoring  MRI.  The  MTT  is  time
that  does  not  vary  much  between  the  WM  and  GM  (5  to
6  s)  and  its  calculation  is  taken  into  account  in  the  arterial
input  function.  With  a  contralateral  lesion  not  allowing  for
a  reliable  contralateral  measurement,  an  absolute  value
of  7  s  may  be  used;
a CBV  under  2  mL/100  g  deﬁnes  an  infracted  zone  with,
as  a  reference,  diffusion  imaging  acquired  at  the  time  of
the  patient’s  admission.
The  zone  of  penumbra  is  therefore  deﬁned  as  a  tissue  in
hich  the  MTT  has  increased  by  145%  from  which  the  zone
f  ischemia  is  subtracted  where  the  CBV  is  <  2  mL/100  g.
hese  values  are  included  in  certain  post-treatment  soft-
are  (Philips  scanners,  for  example)  that  directly  provides
olor  mapping  of  these  two  parameters  (Fig.  1).
Finally,  very  recent  studies  [12]  emphasize  other  param-
ters  and  thresholds,  by  referring  to  control  by  diffusion
RI  at  24  h  and  clinical  scores  after  24  h  and  D90.  A  relative
elay  (time  close  to  the  Tmax used  in  MRI  [see  infra],  but
ree  of  the  arterial  input  function)  greater  than  2  s  and  a
BF  under  40%  that  of  the  contralateral  tissue  would  be  the
ptimum  parameters  to  deﬁne  the  tissue  at  risk  and  infarc-
ion,  respectively.  These  research  tools  have  to  be  perfected
efore  they  can  be  clinically  used.
In  parallel,  the  hemodynamic  consequences  of  acute  or
hronic  stenosis  are  assessed  by  perfusion  CT,  as  are  the
henomena  of  revascularization  after  surgery.
It’s  still  difﬁcult  with  CT  to  study  the  posterior  cerebral
ossa  and  detect  small  lesions.  This  isn’t  the  case  with  MRI.
We  propose  a  perfusion  CT  protocol  (Appendix  I).erfusion MRI
he  diffusion  sequence  directly  visualizes  the  ischemic
ecrosis  in  the  form  of  a  cytotoxic  edema.  The  reduction
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Figure 1. Right hemiplegia occurring 3½ h before: a: the CT-scan shows early signs of CVA; b: the perfusion CT shows an extensive seat
of ischemia of the left sylvian territory with mismatch. The red ROI corresponds to the necrosis (CBV < 2 mmL/100 g, reduction in CBF), the
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CT-angiography shows thrombosis of the left middle cerebral artery
in  the  ADC  beyond  a  certain  threshold  attests  to  an
‘‘irreversible’’  necrosis.  It  is  therefore  logical  to  look  for
the  parameters  and  thresholds  deﬁning  the  tissue  at  risk  in
the  MRI  diffusion/perfusion  association,  as  well  as  in  the  CT
[13]  (Fig.  2).  An  absolute  quantiﬁcation  isn’t  always  possible
in  perfusion  MRI  and  it  is  necessary  to  avoid  confusing  mis-
match  and  penumbra.  Two  studies  have  tried  to  describe  the
MRI  proﬁles  of  patients  who  could  beneﬁt  from  intravenous
thrombolysis.  The  DEFUSE  study  [14]  compiled  74  patients
all  of  whom  beneﬁted  from  an  injection  of  tPA  within  3
to  6  h  after  the  onset  of  the  neurological  deﬁciency,  irre-
gardless  of  the  MRI  data  associating  diffusion  and  perfusion.
The  main  result  that  supports  the  initial  hypothesis  is  that
only  patients  presenting  a  mismatch  beneﬁted  from  a  better
neurological  recovery  with  early  reperfusion.  The  mismatch
criteria  are:  a  deﬁned  lesion  on  the  perfusion  series  using
the  mapping  of  Tmax over  2  s,  and  size  at  least  20%  greater
than  that  measured  from  the  diffusion  sequence.  The  Tmax
e
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N
ivation of CBV and over 300% extension of the MTT); c and d: the
nd dissection of the inner carotid (d).
ay  be  deﬁned  as  the  time  before  the  gadolinium  concen-
ration  peak  is  reached  compared  with  the  arrival  of  the
adolinium  in  the  cerebral  arteries.  The  perfusion  is  deﬁned
s  a  30%-reduction  in  the  volume  of  the  hypoperfused  zone
n  the  control  MRI  carried  out  6  h  after  the  thrombolysis.  The
PITHET  study  [15]  tested  the  hypothesis  that  the  presence
f  a  mismatch  predicts  a  response  to  the  thrombolysis.  This
andomized  study,  compared  a  group  of  52  patients  receiv-
ng  alteplase  with  a  group  of  49  patients  receiving  a  placebo
or  a CVA  occurring  within  3  to  6  h,  after  an  assessment  by
iffusion  and  perfusion  MRI  and  independent  of  the  results
btained.  Control  MRI  was  carried  out  three  to  ﬁve  days  after
he  initial  assessment  and  then  90  days  later.  Reperfusion
as  deﬁned  as  a  90%  reduction  in  he  volume  of  the  hypop-
rfused  zone  on  the  control  MRI  carried  out  within  ﬁve  days
f  the  thrombolysis.  The  clinical  state  was  assessed  using  an
IHSS  score.  In  this  study,  the  tPA  does  not  provide  a  signif-
cant  reduction  in  the  growth  of  the  CVA  in  a  ﬁrst  analysis,
1244  S.  Grand  et  al.
Figure 2. Right hemiplegia and aphasia occurring 2 to 3 h before, noted upon waking up: a: the cytotoxic edema is not very extensive in
the diffusion series; b: the ischemia is still not FLAIR visible; c—f: mismatch between the perfusion data (mapping of CBV: c: T0; d: Tc; e:
MTT; f: the diffusion data; g: corresponding perfusion curves; h: thrombosis of the left inner carotid.
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but  signiﬁcantly  increases  the  reperfusion  in  patients  with
mismatch,  itself  associated  with  a  better  clinical  recovery.
Therefore,  the  patients  with  a  lesion  deﬁned  in  perfusion
by  Tmax mapping  superior  to  2  s  with  a  volume  superior  to
120%  of  the  lesion  in  diffusion  may  beneﬁt  from  treatment
with  tPA  beyond  a  period  of  3  h,  that  is  between  3  and  6  h.
The  perfusion/diffusion  MRI  also  helps  identify  and  elim-
inate  poor  candidates  for  thrombolysis.  These  patients  with
a  high  risk  of  hemorrhage  present  an  ischemic  seat  exceed-
ing  100  mL  in  diffusion  and/or  perfusion  anomalies  deﬁned
by  a  Tmax superior  to  8  s  in  a  volume  of  100  mL  and  more  [14].
The  quantiﬁcations  obtained  from  the  DEFUSE  and  EPI-
THET  studies  have  been  reﬁned.  Studies  carried  out  in  2009
show  that  part  of  the  lesions  initially  visible  in  diffusion  are
reversible  [16]  and  retain  a  Tmax superior  to  4  s  to  predict  the
ﬁnal  size  of  the  infarction  in  case  of  non  reperfusion  and  a
Tmax between  4  and  6  s  to  best  estimate  the  penumbra  [17].
Lansberg  et  al.  [18]  proposed  an  automated  and  fast  post-
treatment  to  differentiate  three  groups  of  patients  with  new
threshold  values:
• patients  with  a  mismatch  (ratio  of  the  damaged  volume
in  perfusion  with  a  Tmax superior  to  6  s and  the  volume
deﬁned  from  the  diffusion  hypersignal  superior  to  1.2)
beneﬁt  from  reperfusion  by  presenting  a  better  clinical
evolution  and  a  reduction  in  the  extension  of  the  infarc-
tion.  The  value  of  6  s  for  the  Tmax is  very  close  to  that
of  5.5  proposed  in  a  study  correlating  positron  emission
tomography  and  perfusion  MRI  for  the  deﬁnition  of  the
penumbra  [19];
• patients  without  mismatch  who  did  not  present  a  clinical
response  or  a  reduction  in  the  extension  of  the  infarction
after  reperfusion;
• patients  with  a  malignant  proﬁle  (volume  damaged  over
100  mL  in  the  diffusion  data  or  with  a  Tmax >  8  s  in  the
perfusion  data)  who  do  not  beneﬁt  from  reperfusion.These  criteria  may  be  of  use  in  the  care  of  the  wake-
up  CVA  [20].  Recently,  Campbell  et  al.  [21]  conﬁrmed  that
rare  cases  of  regressive  lesions  in  diffusion  do  not  alter  the
calculation  of  the  mismatch.
l
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Figure 3. Subarachnoid hemorrhage by rupture of an aneurism: a: appe
b: over 6.5 s increase in the MTT in the sylvian and right anterior cerebr1245
To  simplify  and  shorten  these  analyses,  teams  apply  the
SPECTS  scores  initially  intended  to  assess  the  topography
f  the  extension  of  the  ischemia  in  CT  with  diffusion  and
erfusion  data  (Tmax)  leading  to  a mismatch  score  [22].
We  propose  a  perfusion  MRI  protocol  (Appendix  II).
elayed cerebral ischemia (DCI) due to a
asospasm
CI  is  a  serious  complication  of  subarachnoid  hemorrhages
SAH),  most  often  due  to  the  rupture  of  a  brain  aneurism
Fig.  3).  The  rate  of  morbi-mortality  is  high,  since  46%  of
he  surviving  patients  suffer  from  cognitive  disorders  [23].
he  vasospasm,  an  inﬂammatory  reaction  of  the  vascular
alls,  occurs  between  D4  and  D21  (with  a  maximum  between
6  and  D12),  especially  if  the  SAH  is  considerable  (high
isher  grade).  This  reaction  is  observed  in  arteriography  in
/3  of  the  patients,  although  its  clinical  translation  is  more
are.  The  patients  present  the  insidious  onset  of  impaired
onsciousness  and  focal  neurological  deﬁciency,  assigning  a
ajor  role  to  the  complementary  examinations  required  to
ake  an  early  diagnosis.  While  the  Doppler  is  only  pertinent
n  the  exploration  of  the  sylvian  artery,  the  CT-angiography
s  little  by  little  replacing  the  angiography  in  the  detec-
ion  of  the  vasospasm,  which  is  classiﬁed  as  moderate  (25
o  50%  reduction  in  the  diameter  of  the  vessels)  or  severe
reduction  exceeding  50%  in  the  diameter  of  the  vessels).
evertheless,  the  absence  of  a vasospasm  does  not  exclude
he  possibility  of  the  occurrence  of  an  ischemia  and  the
resence  of  a  vasospasm  does  not  prove  the  ischemia.  Only
alf  of  the  patients  with  a severe  vasospasm  present  a
elayed  ischemia.  The  reduction  in  cerebral  perfusion  due
o  the  vasospasm  is  therefore  not  the  only  factor  respon-
ible  for  the  ischemia  [24].  This  would  explain  why  the
essels  with  the  most  severe  vasospasm  correspond  to  the
ess  perfused  region  in  only  2/3  of  the  cases.  This  is  why
t’s  necessary  to  look  for  a  technique  providing  arguments
s  soon  as  the  onset  of  the  clinical  signs  corroborate  the
schemic  hypothesis.  Perfusion  CT  is  routinely  used  in  the
arance of a diffuse vasospasm of the sylvian arteries in the controls;
al territories with the drop in the CBF.
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iagnosis  of  acute  ischemia.  Its  value  in  delayed  ischemia
as  only  been  recently  demonstrated.  Thresholds  on  the  per-
usion  CT  have  been  proposed  to  corroborate  the  diagnosis
f  vasospasm.  For  Wintermark  et  al.  [25],  an  increase  in  the
TT  above  6.4  s  reveals  a  high  risk  for  DCI,  and  the  arterial
erritory  should  be  evaluated  in  CT-angiography  to  search
or  a  reduction  in  the  diameter  of  the  arteries  that  will  lead
o  an  angiography  for  diagnostic  and  therapeutic  purposes.
ccording  to  Dankbaar  et  al.  [26],  the  MTT  threshold  is  5.9  s
r  a  1.1  s  difference  with  the  contralateral  ROI.  A  relative
ncrease  in  the  MTT  (exceeding  146%  in  the  reference  region)
as  also  been  proposed  [27].
The  qualitative  analysis  [28]  visually  assessing  the  map-
ing  of  MTT,  CBV  and  CBF  would  sufﬁce  to  demonstrate  the
uperiority  of  perfusion  CT  over  CT-angiography  (sensitiv-
ty  of  0.84%  versus  0.64,  speciﬁcity  0.79%  versus  0.5),  the
old  standard  to  make  the  diagnosis  of  delayed  ischemia
eing  the  analysis  of  the  entire  clinical  ﬁle  by  two  expe-
ienced  neurologists.  This  visual  approach  has  already
een  proposed  in  comparison  with  angiography,  with  a
ery  high  sensitivity  (92%)  and  speciﬁcity  of  the  MTT
86%)  [29].
In  practice,  the  interpretation  of  the  perfusion  CT
n  the  search  for  DCI  is  difﬁcult.  It’s  ﬁrst  necessary  to
erify  the  dynamics  of  the  arterial  and  venous  curves.
s  opposed  to  acute  ischemia,  the  pathology  is  diffuse.
t’s  necessary  to  avoid  placing  the  measurement  of  the
rterial  input  function  used  for  the  de-convolution  in  a
athological  zone,  as  this  would  make  any  interpretation
rroneous.  It  may  be  advisable  to  place  a  ROI  in  the  terri-
ories  of  the  lenticuostriate  arteries,  not  very  affected  by
he  DCI.
umor disease
RI  dominates  the  exploration  of  brain  tumors  due  to  its
reat  sensitivity,  in  particular  via  the  T2-weighted/FLAIR
equences,  to  detect  tumor  inﬁltration  at  a  distance
rom  the  main  lesion.  The  morphological  assessment  of
n  expansive  process  includes  T1-weighted  sequences,
2-weighted/FLAIR  sequences,  T1-weighted  sequences
fter  the  injection  of  gadolinium.  An  enhancement  after
njection  only  attests  to  a  rupture  of  the  blood-brain
arrier  (BBB)  and  not  the  presence  of  neo-vessels.  However,
he  characterization  of  the  vascularization  of  a  tumor  is
undamental  to  approach  the  histological  diagnosis  and
ssess  the  grade  of  evolution,  in  particular  in  case  of
lioma.  The  appearance  of  a  neo-angiogenesis  within  a
lioma  is  an  evolutive  and  decisive  turning  point  in  the
isease.  These  neo-vessels  present  an  increase  in  their
iameter,  their  permeability  and  their  density,  as  well  as
ndothelial  proliferation.  Only  perfusion  techniques  give
ccess  to  tumor  microvascularization.  First  pass  perfusion  is
he  technique  most  often  used  in  the  diagnosis  of  the  tumor.
t  can  measure  the  relative  cerebral  blood  volume  in  the
umor  (ratio  between  the  highest  blood  volume  registered
ithin  the  tumor  and  the  blood  volume  registered  in  the
ealthy  contralateral  white  matter),  as  well  as  the  capillary
ermeability.  These  two  parameters  have  to  be  assessed,
r  even  quantiﬁed  when  possible  with  the  post-treatment
oftware.
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lial tumors
he  presence  or  absence  of  enhancement  is  not  enough  to
lassify  gliomas  as  low  or  high  grade  [30].  For  many  years
ow,  the  histological  grade  of  gliomas  has  been  correlated
ith  the  tumor  blood  volume.  The  greater  the  increase
n  volume,  the  higher  the  grade  [1,31,32]  (Fig.  4).  Below
 threshold  of  1.5,  it’s  possible  to  exclude  the  possibility
f  a malignant  glioma  [33], whereas  a  threshold  of  1.75
dentiﬁes  high  grade  gliomas  with  a  sensitivity,  speciﬁcity,
ositive  predictive  value  and  negative  predictive  value  of
5%,  57,5%,  87%,  and  79.3%  respectively  [34].  The  cerebral
lood  volume  is  often  underestimated  due  to  the  increased
ermeability  of  tumor  vessels  and  the  T1-weighted  effects
nduced.  The  injection  of  a  bolus  of  contrast  agent  prior
o  the  acquisition  of  the  ﬁrst  pass  perfusion  series  is  rec-
mmended  in  order  to  correct  them  [35].  However,  this
re-injection  will  mask  the  passage  below  the  baseline,
bserved  in  case  of  lymphoma,  for  example,  which  is  a
ertinent  diagnostic  criterion.  Independently  of  this  histo-
ogical  criteria,  the  CBV  has  a  predictive  value  in  knowing
he  mean  survival  before  progression:  below  1.75,  it’s  3585
ays;  above  1.75,  it’s  265  days  [36].  A  higher  prognostic
alue  (2.2)  is  retained  in  case  of  oligodendroglioma  [37].  The
ermeability,  assessed  by  a  parameter  called  Ktrans  is  also
orrelated  with  the  histological  grade,  although  less  than
he  CBV  [38].  With  a  low-grade  glioma,  the  permeability  and
nhancement  play  an  unfavorable  prognostic  role  [39].
It  should  be  noted  that  the  CBV  of  oligodendrogliomas  is
n  the  average  higher  than  that  of  astrocytomas  [40]  and
hat  certain  oligodendrogliomas  present  seats  of  hypervas-
ularization  due  to  a  rich  capillary  network,  while  remaining
istologically  benign  [33].
In  practice,  the  detection  of  a  seat  of  neo-vascularization
ithin  a  neoplastic  process  indicating  a  low-grade  glioma
hould  be  the  target  of  the  biopsy,  since  it  corresponds  to
 suspected  highly  malignant  zone  [41]. The  appearance
f  a  seat  of  neo-vascularization  during  the  monitoring  of
 low-grade  glioma  suggests  the  evolution  towards  a  high
rade  tumor  (Fig.  5) and  most  often  leads  to  a  change  or
esumption  of  therapy.
During  the  monitoring  of  gliomas,  it’s  fundamental  to
lways  use  the  same  acquisition  protocol  in  order  to  obtain
omparable  explorations  [42].  In  particular,  the  controls
hould  always  be  carried  out  on  the  same  MRI  machine  when
wo  machines  with  different  ﬁelds  are  available.
Radiotherapy  and  chemotherapy  induce  post-therapeutic
earrangements  and  it’s  difﬁcult  to  interpret  the  morpho-
ogical  images  according  to  MacDonald’s  et  al.  criteria
43]. Pseudo-progression  corresponds  to  an  increase  in  the
olume  of  the  enhancement,  whether  or  not  associated
ith  an  increase  in  clinical  deﬁciency.  Radiotherapy,  whose
ffects  are  potentiated  by  chemotherapy,  provokes  inﬂam-
atory  phenomena,  endothelial  lesions,  with  an  increase
n  capillary  permeability  and  the  presence  of  an  edema.
 reduction  in  the  CBV  indicates  a  pseudo-progression,
hereas  an  increase  suggests  tumor  evolution  [44].  A  thresh-
ld  of  two  was  proposed  to  differentiate  tumor  recurrence
nd  post-therapeutic  effects,  such  as  radionecrosis,  in  a
tudy  that  integrates  spectroscopic  data  [45],  opening  the
ay  to  multimodal  MRI.  The  pseudo-response  is  a  reduction
n  the  volume  of  the  enhancement  due  to  the  use  of  an
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larization extends beyond the enhancement; c: the CBV ratio bet
9.2.
antiangiogenic  agent  such  as  Bevacizumab  that  closes  the
blood-brain  barrier  and  reduces  neo-vascularization.  The
spectacular  results  observed  in  the  ﬁrst  days  of  treatment
are  not  necessarily  correlated  with  a  clinical  improvement.
The  T2-weighted  and  FLAIR  sequences  are  then  fully  useful
along  with  the  description  of  the  RANO  criteria  [46].
Based  on  this  data,  we  ﬁnd  that  it’s  obligatory  to  inter-
pret  the  MRI  with  an  exact  understanding  of  the  therapeutic
treatment  regimen.
Pilocytic  astrocytoma  (Fig.  6)  is  a  speciﬁc  grade  1  glioma
according  to  the  WHO,  presenting  a  low  CBV  (close  to  1)  and
a  high  permeability.  These  characteristics  differentiate  it
from  a  hemangioblastoma  that  resembles  it  morphologically
(cystic  tumor  with  ﬂeshy  nodule  of  the  posterior  cerebral
fossa)  [47,48],  but  that  presents  a  very  distinct  hypervascu-
larization.
LymphomaThe  incidence  of  malignant  non-hodgkin  lymphoma  (NHL)
is  increasing.  The  diagnosis  of  lymphoma  as  of  the  MRI
helps  avoid  starting  corticotherapy,  which  may  eliminate
the  lesion  and  render  a  biopsy  impossible.  The  lymphoma
T
1
drization is visible on the mapping of the CBV; b: this hypervascu-
 the neoplastic zone and the healthy zone is very high, reaching
resents  characteristics  in  diffusion  as  well  as  in  perfusion.
n  diffusion,  there  is  a reduction  in  the  ADC  related  to
he  very  cellular  nature  of  the  tumor.  In  perfusion,  the
BV  is  low,  close  to  1.5  [49,50]  and  the  baseline  very  dis-
inctly  passes  above  its  initial  value  (Fig.  7).  This  data  is
articularly  useful  in  identifying  the  meningeal  forms  of
he  lymphomas  that  are  thereby  distinguished  from  menin-
iomas  and  meningeal  metastases  and  to  detect  the  multiple
ymphomatous  sites.
Besides  the  CBV,  other  parameters  may  be  analyzed,  such
s  the  percentage  signal  recovery  (PSR)  that  corresponds
o  the  minimum  difference  in  signal  over  the  difference
etween  the  minimum  signal  and  baseline  [51].  The  advan-
age  of  the  PSR  is  that  it  integrates  the  idea  of  permeability
ttested  to  by  the  passage  above  the  baseline  of  the  per-
usion  curve.  Lymphomas  are  characterized  [52]  by  high  PSR
eans  and  maximums.
eningiomashe  World  Health  Organization  classiﬁcation  of  tumors  lists
5  sub-types  of  meningiomas.  It’s  therefore  difﬁcult  to
escribe  the  general  criteria  of  vascularization  for  all  of
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hese  meningiomas.  The  CBV  of  angiomatous  meningiomas
s  higher  than  that  of  meningiothelial  meningiomas,  itself
igher  than  that  of  ﬁbroblastic  meningiomas  [53].  A  high  CBV
n  a  peri-lesional  edema  suggests  an  anaplastic  meningioma
54].
In  medical  practice,  a  highly  hypervascularized  extra-
xial  tumor  indicates  a  meningioma  rather  than  a
chwannoma  [55]  or  a  dural  metastasis  [56],  although
ypervascular  metastases  may  induce  an  error.  A  highly
ypervascularized  intra-ventricular  tumor  indicates  a
eningioma  rather  than  a  neurocytoma  or  subependymoma
Fig.  8)  [57].
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igure 5. Monitoring of a low-grade inﬁltrating glioma: a and b: im
ypervascularization; e: the CBV ration reaches 4; f: the Choline/Crea
owards malignancy.S.  Grand  et  al.
etastases
ery  frequent,  brain  metastases  are  hypervascular.  If  they
re  alone  and  if  a  neoplastic  antecedent  is  not  known,
he  differential  diagnosis  with  a  malignant  glial  cell  tumor
s  difﬁcult.  The  PSR  of  metastases  is  statistically  lower
han  that  of  malignant  gliomas  [52].  The  study  of  the  peri-
umoral  environment  helps  differentiate  the  two  diagnostic
ypotheses.  The  CBV  observed  in  a  peri-tumoral  zone  with metastasis  is  lower  than  that  observed  with  a  malig-
ant  glioma  [58]  due  to  the  peri-lesional  tumor  inﬁltration
bserved  with  a  glioma.  This  semiological  sign,  when  it
aging during the monitoring; c: appearance of enhancement; d:
tine ratio equals 4.2. All of the data indicates a focal evolution
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Figure 6. Pilocytic astrocytoma revealed by headache since one month in a 7-year old child: a: mass next to the fourth ventricle; b: the
enhancement of the mass is heterogenous; c: the perfusion curves in the healthy zone (green) and the neoplastic zone (red) do not reveal
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•an increase in the CBV in the tumor, but an increase in the permeab
exists,  seems  most  reliable  in  clinical  practice  to  distinguish
the  quantitative  data  of  two  tumor  entities,  even  if  it  often
overlaps.
Pseudo-tumoral process
Abscess
Rare,  the  brain  abscess,  from  a  clinical  as  well  as  a  radio-
logical  viewpoint,  suggests  the  possibility  of  a  primary  or
secondary  malignant  tumor.  The  diffusion  series,  that  shows
a  low  ADC  within  the  purulent  necrosis,  is  the  key  to  the
diagnosis.  The  perfusion,  by  revealing  a  little  vascularized,
abscess  capsule  [59],  rich  in  collagen  ﬁbers,  is  a  comple-
mentary  non-useable  series  in  the  case  under  discussion  [60]
(Fig.  9).  This  characteristic,  like  any  semiological  sign,  may
be  erroneous  [61],  thereby  emphasizing  the  importance  of
multimodal  approaches  associating  perfusion,  diffusion  and
spectroscopy  [62].
Demyelinating  lesions
Extensive  areas  of  demyelination  may  imitate  a  tumor  [63].
When  the  pseudo-tumor  is  present  during  the  ﬁrst  attack
of  multiple  sclerosis  or  when  this  is  a  single  episode  (acute
disseminated  encephalomyelitis),  the  radiological  diagnosis
is  difﬁcult.  The  lesions  appear  as  enhanced  masses,  often
surrounded  by  an  edema.  However,  the  mean  CBV  of  these
N
T
i (passage above the baseline of the perfusion curve).
esions  is  under  one  [64],  differing  greatly  from  that  of
alignant  brain  tumors  (Fig.  10).
Parallel  to  the  quantitative  perfusion  data,  the  small
eins  along  which  demyelinating  areas  are  visible  through
he  effect  of  magnetic  susceptibility  on  the  native  slices,
hen  orient  the  diagnosis.
alue of CT in tumor disease
T  is  less  pertinent  than  MRI  in  the  assessment  of  the  exten-
ion  of  tumors.  Nevertheless,  it  has  several  advantages  [65]:
the  lineal  relationship  between  the  concentration  of
the  contrast  product  and  the  attenuation  of  the  X-rays
provides  more  robust  estimates  of  the  CBV  and  the  per-
meability;
it  isn’t  sensitive  to  the  effects  of  magnetic  susceptibil-
ity  related  to  post-therapeutic  rearrangements  that  often
perturb  the  interpretation  of  the  MRI  during  the  monitor-
ing  [66];
with  only  one  acquisition,  it  provides  access  to  the  usual
parameters  (CBV,  CBF,  MTT)  as  well  as  the  permeability
data.eurodegenerative disease
he  diagnosis  of  dementia,  especially  in  Alzheimer’s  disease,
s  based  on  the  clinical  data  and  the  neuropsychological
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Figure 7. Lymphoma revealed by recent headache in a 65-year-old man: a: obstructive lesion of the interventricular foramen; b: the mass
is massively enhanced; c: CBV ration slightly lower than one and major permeability of the neoplastic vessels (very pronounced passage
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sbove the baseline of the perfusion curve).
ests.  Morphological  imaging  (MRI)  should  be  obtained  in
rder  to  eliminate  the  tumoral  or  vascular  causes  and  look
or  speciﬁc  zones  of  atrophy.  In  atypical  cases,  it’s  pos-
ible  to  use  biological  markers  in  the  LCR  (tau  protein
nd  abeta  42)  and  metabolic  data  derived  from  scintig-
aphy  or  positon  emission  tomography.  These  expensive
xaminations  detect  regions  of  hypo-metabolism  that  may
b
M
r
[e  replaced  by  spin  labeling  MRI,  not  requiring  an  injec-
ion,  and  provide  both  a  morphological  and  a  functional
tudy.  For  example,  a  high  correlation  has  been  found
etween  positron  emission  tomography  and  spin  labeling
RI,  both  showing  angular  gyri  impairment  or  the  poste-
ior  part  of  the  cingulated  cortex  in  Alzheimer’s  disease
67,68].
Perfusion  imaging  in  brain  disease  1251
Figure 8. Meningioma developing in the 4th ventricle in a 72-year-old woman: a: the enhancement of the mass is homogenous; b: it is
hypervascular on the CBV mapping; c: the CBV ratio equals 15.
1252  S.  Grand  et  al.
Figure 9. Toxoplasmosis revealing HIV seropositivity in a 42-year-old man  consulting for right hemibody sensory disorders: a: left thalamic
lesion surrounded by an edema; b: this lesion is massively enhanced; c: it does not present hypervascularization; d: there is an increase in
capillary permeability.
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Figure 10. a: CT without injection; b: perfusion CT (CBF); c: angioscan; d: FLAIR; e: mapping of the ADC.
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as  in  the  CT-scan  is  generated.
The  ROI  vary:  in  ischemic  disease,  the  ROI  describe  the254  
onclusion
erfusion  CT  and  MRI  are  an  integral  part  of  a  neuroradi-
logical  assessment.  Ischemic  and  tumor  disease  are  two
ajor  groups  in  which  they  play  a  preponderant  role.  Their
ole  in  epileptic  and  neurodegenerative  disease  is  being
tudied.
TAKE-HOME  MESSAGES
Acute  ischemic  disease:
• perfusion  CT  and  MRI  should  assess  the  brain  tissue
at  risk  (penumbra)  in  case  of  acute  CVA;
• quantitative  values  are  recognized  in  perfusion  CT:  a
CBV  <  2  mL/100  g  deﬁnes  the  infracted  zone,  a  145%
increase  in  the  MTT  deﬁnes  the  penumbra;
• MRI  is  used  to  identify  the  good  candidates  for
thrombolysis  (positive  mismatch)  and  exclude  the
bad  candidates  with  a  high  risk  of  hemorrhage;
• the  quantitative  data  should  be  made  more  exact  by
perfusion  MRI.
Delayed  ischemia  (vasospasm):
• perfusion  CT  and  CT-angiography  should  replace
angiography  in  the  diagnosis  of  vasospasm.  The
MTT  is  the  most  important  parameter  to  determine
(thresholds  need  to  be  speciﬁed).
Tumor  disease:
• the  perfusion  curves  of  lymphoma  and  pilocytic
astrocytoma  are  similar.  The  CBV  ratio  is  close  to  1,
the  passage  above  the  baseline  is  very  distinct;
• the  higher  the  grade  of  the  glioma,  the  higher  the
CBV;
• the  CBV  of  gliomas,  independent  of  the  histological
grade,  predicts  the  mean  survival  before
progression;
• the  appearance  of  neurovascularization  within  a  low-
grade  glioma  indicates  tumoral  evolutivity  towards  a
higher  grade;
• the  threshold  of  two  helps  differentiate  tumor
recurrence  from  radionecrosis.
linical case
ix  days  ago,  this  77-year-old  woman  beneﬁted  from
ight  carotid  endarterectomy  for  very  tight  bulbar  and
ost-bulbar  stenosis,  revealed  by  paresthesia  of  the  right
emibody.  She  consulted  for  seizures  of  the  face  and  arm.
uestions
.  Does  this  case  involve  a  post  endarterectomy  CVA?
.  What  factors  favor  a  brain  reperfusion  syndrome?
a)  Poorly  controlled  HBP
b)  Antecedents  of  CVA
c)  Tight  arterial  stenosis
d)  A  deﬁcient  cerebral  blood  ﬂow  in  transcranial  Doppler
before  surgery
v
t
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.  How  do  you  account  for  the  perfusion  data  (CBF)?
.  What  is  your  diagnosis?
nswers
.  There’s  an  increase  in  ADC,  the  lesion  therefore  corre-
spond  to  a  vasogenic  and  not  cytotoxic  edema.
.  a,  b,  c,  d.
.  There’s  an  increase  in  CBF  since  there  is  a  loss  of  cerebral
vascular  autoregulation.
.  Diagnosis:  vasogenic  edema  by  brain  reperfusion  syn-
drome.
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ppendix I. Perfusion CT protocol
he  last  generation  of  scanners  almost  completely  covers
f  the  brain  and  brain  perfusion  isn’t  limited  to  2  cm  as
efore.  The  positioning  of  the  perfusion  series  is  related  to
he  clinical  deﬁciency  and  most  probable  topography  of  the
eat  of  the  ischemia.  After  a  series  without  injection,  the
ext  step  consists  of  the  acquisition  of  images  in  dynamic
ode,  at  the  rate  of  eight  joint  slices,  each  with  a  thick-
ess  of  5  mm,  for  40  s  (one  image  every  two  seconds)  during
he  intravenous  peripheral  injection  of  a  bolus  of  40  mL  of
MNIPAQUE  300  (iohexol  300  mgI/mL,  GE  Healthcare®)  at
 mL/sec  in  a  peripheral  vein  (cathlon  20G),  using  an  auto-
atic  injector  (SWISS  MEDICAL  CARE).  The  injection  lasts
or  10  s.  The  acquisition  begins  6  s  after  the  beginning  of  the
njection  and  lasts  for  40  s.  One  hundred  and  sixty  images
re  acquired  during  this  period,  that  is,  20  images  for  each
f  the  eight  slice  levels,  at  a  rate  of  one  image  every  2  s.
his  protocol  thereby  provides  eight  CT  brain  slices,  each
 mm  thick,  or  a  volume  of  40  mm.  The  mapping  of  the  CBV,
BF,  MTT  and  TTP  is  generated,  giving  quick  access  to  a  ﬁrst
ualitative  analysis.  ROI  representing  the  arterial  territo-
ies  are  positioned  for  the  calculation  of  the  quantitative
ata.
ppendix II. Perfusion MRI protocol
n  echo  gradient  sequence  is  usually  used  (for  example,
t  1.5  T,  a  multishot  sequence  with  RT  =  507  ms,  ET  =  30  ms,
ngle  =  40◦, 12  slices  5.5  mm  thick  obtained  every  1.5  s  for
ne  minute);  the  injection  is  carried  out  with  the  usual
osage  (0.2  mL/kg  or  0.1  mmol/kg)  with  a  ﬂow  of  6  mL/s,
oncomitant  to  the  dynamic  acquisition.  The  same  mappingascular  territories,  in  tumor  disease,  a ROI  is  positioned  in
he  zone  where  the  CBV  is  highest,  another  in  the  contralat-
ral  white  matter  to  form  the  CBVtumor/CBVwhite matter ratio
epresentative  of  the  tumor.
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